PURPOSE: We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831 adjuvant trastuzumab trial. PATIENTS AND METHODS: All patients (N = 1,888) underwent chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel with or without concurrent trastuzumab. HER2 status was determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) at a central laboratory, Mayo Clinic, Rochester, MN. Patients with conflicting local positive HER2 expression results but normal central laboratory testing were included in the analyses (n = 103). RESULTS: Patients with HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥ 2.0, or both) benefited from trastuzumab, with hazard ratios (HRs) of 0.46, 0.49, and 0.45, respectively (all P < .0001). Patients with HER2-amplified tumors with polysomic (p17) or normal (n17) chromosome 17 copy number also benefited from trastuzumab, with HRs of 0.52 and 0.37, respectively (P < .006). Patients who received chemotherapy alone and had HER2-amplified and p17 tumors had a longer DFS than those who had n17 (78% v 68%; P = .04), irrespective of hormone receptor status or tumor grade. Patients with HER2-normal tumors by central testing (n = 103) seemed to benefit from trastuzumab, but the difference was not statistically significant (HR, 0.51; P = .14). Patients with hormone receptor-positive or -negative tumors benefited from the addition of trastuzumab, with HRs of 0.42 (P = .005) and 0.60 (P = .0001), respectively. CONCLUSION: These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.
PURPOSE: We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831 adjuvant trastuzumab trial. PATIENTS AND METHODS: All patients (N = 1,888) underwent chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel with or without concurrent trastuzumab. HER2 status was determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) at a central laboratory, Mayo Clinic, Rochester, MN. Patients with conflicting local positive HER2 expression results but normal central laboratory testing were included in the analyses (n = 103). RESULTS:Patients with HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥ 2.0, or both) benefited from trastuzumab, with hazard ratios (HRs) of 0.46, 0.49, and 0.45, respectively (all P < .0001). Patients with HER2-amplified tumors with polysomic (p17) or normal (n17) chromosome 17 copy number also benefited from trastuzumab, with HRs of 0.52 and 0.37, respectively (P < .006). Patients who received chemotherapy alone and had HER2-amplified and p17tumors had a longer DFS than those who had n17 (78% v 68%; P = .04), irrespective of hormone receptor status or tumor grade. Patients with HER2-normal tumors by central testing (n = 103) seemed to benefit from trastuzumab, but the difference was not statistically significant (HR, 0.51; P = .14). Patients with hormone receptor-positive or -negative tumors benefited from the addition of trastuzumab, with HRs of 0.42 (P = .005) and 0.60 (P = .0001), respectively. CONCLUSION: These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.
Authors: F Peintinger; A U Buzdar; H M Kuerer; J A Mejia; C Hatzis; A M Gonzalez-Angulo; L Pusztai; F J Esteva; S S Dawood; M C Green; G N Hortobagyi; W F Symmans Journal: Ann Oncol Date: 2008-07-29 Impact factor: 32.976
Authors: C Marchiò; R Natrajan; K K Shiu; M B K Lambros; S M Rodriguez-Pinilla; D S P Tan; C J Lord; D Hungermann; K Fenwick; N Tamber; A Mackay; J Palacios; A Sapino; H Buerger; A Ashworth; J S Reis-Filho Journal: J Pathol Date: 2008-12 Impact factor: 7.996
Authors: M Untch; R D Gelber; C Jackisch; M Procter; J Baselga; R Bell; D Cameron; M Bari; I Smith; B Leyland-Jones; E de Azambuja; P Wermuth; R Khasanov; F Feng-Yi; C Constantin; J I Mayordomo; C-H Su; S-Y Yu; A Lluch; E Senkus-Konefka; C Price; F Haslbauer; T Suarez Sahui; V Srimuninnimit; M Colleoni; A S Coates; M J Piccart-Gebhart; A Goldhirsch Journal: Ann Oncol Date: 2008-02-21 Impact factor: 32.976
Authors: Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins Journal: Lancet Oncol Date: 2009-03 Impact factor: 41.316
Authors: M Hofmann; O Stoss; T Gaiser; H Kneitz; P Heinmöller; T Gutjahr; M Kaufmann; T Henkel; J Rüschoff Journal: J Clin Pathol Date: 2007-04-05 Impact factor: 3.411
Authors: Mitch Dowsett; Marion Procter; Worta McCaskill-Stevens; Evandro de Azambuja; Urania Dafni; Josef Rueschoff; Bruce Jordan; Stella Dolci; Mark Abramovitz; Oliver Stoss; Giuseppe Viale; Richard D Gelber; Martine Piccart-Gebhart; Brian Leyland-Jones Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Cleo Yi-Fang Lee; Yuan Lin; Scott V Bratman; Weiguo Feng; Angera H Kuo; Ferenc A Scheeren; Jesse M Engreitz; Sushama Varma; Robert B West; Maximilian Diehn Journal: Cancer Res Date: 2013-10-31 Impact factor: 12.701
Authors: Morgan Ballard; Florencia Jalikis; Gregor Krings; Rodney A Schmidt; Yunn-Yi Chen; Mara H Rendi; Suzanne M Dintzis; Kristin C Jensen; Robert B West; Richard K Sibley; Megan L Troxell; Kimberly H Allison Journal: Mod Pathol Date: 2016-10-14 Impact factor: 7.842
Authors: Nadire Duru; Ming Fan; Demet Candas; Cheikh Menaa; Hsin-Chen Liu; Danupon Nantajit; Yunfei Wen; Kai Xiao; Angela Eldridge; Brett A Chromy; Shiyong Li; Douglas R Spitz; Kit S Lam; Max S Wicha; Jian Jian Li Journal: Clin Cancer Res Date: 2012-10-22 Impact factor: 12.531
Authors: Suthinee Ithimakin; Kathleen C Day; Fayaz Malik; Qin Zen; Scott J Dawsey; Tom F Bersano-Begey; Ahmed A Quraishi; Kathleen Woods Ignatoski; Stephanie Daignault; April Davis; Christopher L Hall; Nallasivam Palanisamy; Amber N Heath; Nader Tawakkol; Tahra K Luther; Shawn G Clouthier; Whitney A Chadwick; Mark L Day; Celina G Kleer; Dafydd G Thomas; Daniel F Hayes; Hasan Korkaya; Max S Wicha Journal: Cancer Res Date: 2013-02-26 Impact factor: 12.701